# A Long Term Study of the Safety of Tanezumab When Administered By Subcutaneous Injections

> **NCT00994890** · PHASE2 · TERMINATED · sponsor: **Pfizer** · enrollment: 679 (actual)

## Conditions studied

- Osteoarthritis, Knee
- Osteoarthritis, Hip

## Interventions

- **DRUG:** Tanezumab 2.5 mg
- **DRUG:** Tanezumab 5 mg
- **DRUG:** Tanezumab 10 mg

## Key facts

- **NCT ID:** NCT00994890
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-11-17
- **Primary completion:** 2010-12-07
- **Final completion:** 2011-03-01
- **Target enrollment:** 679 (ACTUAL)
- **Why stopped:** See termination reason in detailed description.
- **Last updated:** 2021-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00994890

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00994890, "A Long Term Study of the Safety of Tanezumab When Administered By Subcutaneous Injections". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT00994890. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*